Exosomal and intracellular miR-320b promotes lymphatic metastasis in esophageal squamous cell carcinoma

Tong Liu,1,5 Peilong Li,1,2,5 Juan Li,1,2,5 Qiuchen Qi,1,2 Zhaowei Sun,3 Shuang Shi,1 Yan Xie,1 Shibiao Liu,1 Yunshan Wang,1,2,4 Lutao Du,1,2,4 and Chuanxin Wang1,2,4

Cancer-cell-released exosomal microRNAs (miRNAs) are important mediators of cell-cell communication in the tumor microenvironment. In this study, we sequenced serum exosome miRNAs from esophageal squamous cell carcinoma (ESCC) patients and identified high expression of miR-320b to be closely associated with peritumoral lymphangiogenesis and lymph node (LN) metastasis. Functionally, miR-320b could be enriched and transferred by ESCC-released exosomes directly to human lymphatic endothelial cells (HLECs), promoting tube formation and migration in vitro and facilitating lymphangiogenesis and LN metastasis in vivo as assessed by gain- and loss-of-function experiments. Furthermore, we found programmed cell death 4 (PDCD4) as a direct target of miR-320b through bioinformatic prediction and luciferase reporter assay. Re-expression of PDCD4 could rescue the effects induced by exosomal miR-320b. Notably, the miR-320b-PDCD4 axis activates the AKT pathway in HLECs independent of vascular endothelial growth factor-C (VEGF-C). Moreover, overexpression of miR-320b promotes the proliferation, migration, invasion, and epithelial-mesenchymal transition progression of ESCC cells. Finally, we demonstrate that METTL3 could interact with DGC8 protein and positively modulate pri-miR-320b maturation process in an N6-methyladenosine (m6A)-dependent manner. Therefore, our findings uncover a VEGF-C-independent mechanism of exosomal and intracellular miR-320b-mediated LN metastasis and identify miR-320b as a novel predictive marker and therapeutic target for LN metastasis in ESCC.

INTRODUCTION
Esophageal cancer (EC) is the eighth most common cancer with the sixth highest mortality rate worldwide.1,2 Among the two major histological subtypes of EC, esophageal squamous cell carcinoma (ESCC) accounts for about 80% of all EC cases.3 Among the various clinical risk factors correlated with ESCC pathogenesis, lymph node (LN) metastasis remains the most important factor for poor outcomes, with 5-year postoperative survival rates in these patients decreasing from 70% to 18%.4 ESCC patients with LN metastasis often present with a more malignant disease course with a higher probability for local and distant relapse, leading to a poor outcomes.4 Despite the abundant evidence for the role of LN metastasis in cancer, the underlying molecular mechanisms that enhance it in ESCC remain unclear.

Lymphangiogenesis is an important process of generating new lymphatic vessels and is involved in LN metastasis in multiple tumors.5,6 Growing evidence shows that lymphatic vessels in the tumor margin act as a channel for tumor cells to transmit from their local site to regional LNs.8 However, the molecular mechanism of tumor-driven peritumoral lymphangiogenesis is not well defined. Among multiple factors underlying lymphatic metastasis, the adaptation of the primary tumor microenvironment by tumor cells to promote metastasis plays a crucial prometastatic role.9 Previous studies suggested that tumor cells secreting VEGF-C is a critical step in ESCC lymphangiogenesis and LN metastasis.10,11 However, about 21% of ESCC patients with LN metastasis show low VEGF-C expression,12 which implies the existence of a VEGF-C-independent mechanism for lymphangiogenesis and LN metastasis in ESCC.

MicroRNAs (miRNAs) are small non-coding RNAs (18–26 nt) that target 3′ untranslated regions (3′ UTRs) of mRNAs, leading to the destabilization and/or posttranscriptional suppression.13 Studies show that dysregulation of various miRNAs is closely related to tumorigenesis, progression, and recurrence.14 Recent reports have
suggested that miR-485-5p inhibits EC proliferation and invasion by downregulating the expression of O-GlcNAc transferase enzyme.\textsuperscript{15} Moreover, miR-134 could modulate the proliferation, apoptosis, and LN metastasis of ESCC via the PLXNA1-mediated MAPK signaling pathway.\textsuperscript{16} In addition, miR-10b-3p is considered an oncogene and a significant prognosis predictor in EC and can promote proliferation, migration, and invasion of ESCC through targeting FOXO3.\textsuperscript{17} Nevertheless, the accurate expression and function of miRNA in ESCC LN metastasis progression has yet to be explored.

Despite previously considered to localize only in cells, miRNAs are now reported to be present extracellularly as a major RNA component in exosomes.\textsuperscript{18} Exosomes are small microvesicles ranging from 30 to 150 nm in size that contain various types of nucleic acids, including miRNAs.\textsuperscript{19,20} Recently, cancer-cell-released exosomes were identified as crucial mediators in cell-cell communication, which correlated with tumor-cell-induced vascular permeability,\textsuperscript{21} premetastatic niche formation,\textsuperscript{22} and bone marrow progenitor cell recruitment in distant organs.\textsuperscript{23} However, the mechanism of cancer-cell-secreted exosome regulation of lymphatic vascular system formation via the induction of lymphangiogenesis remains unknown, warranting further exploration.

In this study, we report that a miRNA, miR-320b, was highly enriched in serum exosomes from patients with ESCC and correlated positively with LN metastasis. Exosomal miR-320b promoted lymphangiogenesis and LN metastasis in vitro and in vivo. Mechanistically, miR-320b was loaded to exosomes and transmitted to human lymphatic endothelial cells (HLECs). Subsequently, miR-320b suppressed programmed cell death 4 (PDCD4) expression and stimulated the AKT signaling pathway, facilitating lymphangiogenesis and LN metastasis in ESCC. Elevated expression of intracellular miR-320b could promote tumor cell proliferation, migration, and invasion through the miR-320b-PDCD4-AKT regulation axis. Our findings highlight a VEGF-C independent mechanism of exosomal and intracellular miR-320b-mediated LN metastasis and identify miR-320b as a potential predictive marker and therapeutic target for LN metastasis in ESCC.

RESULTS

**Upregulation of serum exosomal miR-320b positively correlates with ESCC LN metastasis**

To identify candidate exosomal miRNAs that play key roles in LN metastasis of ESCC, we first performed genome-wide miRNA next generation sequencing (NGS)-based miRNA expression profiling for 20 serum exosomes of ESCC patients (10 LN\textsuperscript{−}N\textsuperscript{5}, 5 N1 stage, and 5 N3 stage cases). As shown in Figure 1A, overlapping differentially expressed miRNA (LN\textsuperscript{+} versus LN\textsuperscript{−}) analysis with differentially expressed miRNA (N1 stage versus N3 stage) analysis, we identified 11 exosomal miRNAs associated with LN metastasis. Subsequently, we excluded the low expression levels of miRNAs (average expression level < 50), which led to the selection of 3 miRNAs (miR-332-5p, miR-652-3p, and miR-320b). The three candidate miRNAs chosen by NGS were first investigated in clinical serum exosome samples consisting of 32 LN\textsuperscript{−} and 32 LN\textsuperscript{+} ESCC patients. Results indicated that only exosomal miR-320b was highly expressed in the LN\textsuperscript{+} group (2.555, 1.104–6.394) compared with the LN\textsuperscript{−} group (0.866, 0.293–2.122; p < 0.001, Figures S1A–S1C). An additional 114 clinical serum exosomal samples from ESCC patients (63 LN\textsuperscript{−} and 51 LN\textsuperscript{+}) were then analyzed with qRT-PCR, to validate the above phenomena. Thus, the training cohort comprised 95 LN\textsuperscript{−} and 83 LN\textsuperscript{+} patients (cohort 1). In the training set, miR-320b was upregulated in LN\textsuperscript{+} patients (3.129, 1.119–6.364) compared with LN\textsuperscript{−} patients (1.117, 0.493–2.346; p < 0.001, Figure 1B). The expression level of miR-320b in patients with N2–3 stage (5.505, 2.682–9.854) was also higher than in patients with N1 stage (2.16, 0.93–4.666; p = 0.002, Figure 1C). Receiver operating characteristic (ROC) curve analyses showed that miR-320b has a strong capability for discriminating LN\textsuperscript{+} patients from LN\textsuperscript{−} patients and distinguishing N1 and N2–3 stage patients with an area under ROC curve (AUC) value of 0.737 (Figure 1D) and 0.707 (Figure 1E) in cohort 1, respectively. The expression level of miR-320b was further confirmed using another independent validation cohort (cohort 2) with 91 LN\textsuperscript{−} and 97 LN\textsuperscript{+} patients. The alterations in the miR-320b expression pattern of the validation cohort agreed with those from the training cohort, with high expression in LN\textsuperscript{+} (2.713, 1.179–5.523) compared with LN\textsuperscript{−} (1.391, 0.483–2.346; p < 0.001,) and N2–3 stage (4.17, 2.289–7.34) compared with N1 stage (2.233, 0.906–4.169; p < 0.001; Figures 1F and 1G). In compliance with the training cohort, the AUC of the cohort 2 was 0.715 and 0.715 (Figures 1H and 1I). Correspondingly, higher exosomal miR-320b levels strongly correlated incrementally with the peritumoral lymphatic vessel density (PLVD) in serial sections of ESCC specimens, as indicated by LYVE1-positive vessels using immunohistochemistry (IHC) analysis (Figure 1J). Correspondingly, Spearman’s correlation analysis indicated that higher miR-320b levels strongly correlated with the increment of PLVD in serial sections of ESCC specimens (r = 0.383, p = 0.002, Figure 1K).

**miR-320b containing exosomes are enriched in ESCC cell-secreted exosomes**

Extracellular miRNAs have essential biological functions such as mediating cell-cell interactions and contributing to tumor LN metastasis. As they are mainly enriched in exosomes in particular,\textsuperscript{24} we then examined miR-320b expression within ESCC-secreted exosomes. Exosomes purified from KYSE150 and EC9706 culture supernatant were detectable by transmission electron microscopy (TEM) and exhibited typical cup-shaped, round morphologies and were between 30 and 150 nm in diameter (Figure 2A). ZetaView analysis showed that the majority of the serum exosomes were 123.7 nm in diameter (Figure 2B). Increased exosome markers CD63 and CD9 protein and decreased levels of β-tubulin were observed compared with whole cells (Figure 2C). Notably, miR-320b was found to be enriched in ESCC-secreted exosomes, in particular, the EC9706 cell line (Figure 2D), relative to other cellular content and compared with exosomes secreted by non-carcinoma epithelial cell line (HET-1A).

To investigate the generation of secreted exosomal miR-320b by ESCC, we transfected a lentiviral vector overexpressing miR-320b or
Figure 1. Exosomal miR-320b is associated with ESCC lymphatic metastasis

(A) Schematic of LN- versus LN+ and N1 versus N3 by NGS analysis for the identification of LN metastasis associated miRNAs. (B and F) qRT-PCR analysis of exosomal miR-320b in serum samples of ESCC patients in two cohorts. (C and G) qRT-PCR analysis of exosomal miR-320b in serum samples of LN+ patients in two cohorts. (D and H) ROC curves for detection of LN metastasis using exosomal miR-320b as assessed by AUC in two cohorts. (E and I) ROC curve analysis of exosomal miR-320b for the discrimination of N stage in ESCC patients in two cohorts. (J) Staining of LYVE-1 protein in ESCC tissue specimens. The lymphatic vessels are indicated by red arrows. Scale bar, 50 μm. (K) Spearman’s correlation analysis between serum exosomal miR-320b expression level and peritumoral lymphatic vessel density (PLVD) in ESCC tissues. ***p < 0.001.
scramble vector into KYSE150 (low miR-320b expressor). Conversely, lentiviral vector miR-320b knockdown or negative control (NC) was transfected into EC9706 (high miR-320b expressor). qRT-PCR analysis revealed that miR-320b expression was significantly higher in KYSE150-secreted exosomes (KYSE150-EXO miR-320b) transfected with miR-320b overexpressing vectors and in NC EC9706-secreted exosomes compared to controls.

**Figure 2. miR-320b is upregulated in ESCC cell-secreted exosomes**

Isolated exosomes were confirmed by TEM (A) and Zetaview analysis (B). Scale bar, 50 nm. (C) Western blot analysis of CD9, CD63, and β-tubulin in lysates of exosomes or cells. (D) qRT-PCR analysis of miR-320b expression in exosomes from KYSE30, KYSE150, TE-1, EC109, EC9706, and HET-1A cells. miR-16 was used as an internal control. (E) qRT-PCR analysis of miR-320b expression in miR-320b overexpressing and control KYSE150 cells released exosomes. (F) qRT-PCR detection of miR-320b expression in miR-320b knocking down and control EC9706 cells released exosomes. (G) qRT-PCR analysis of miR-320b in the EC9706 cell-derived exosomes by treatment with PBS, RNase A (10 μg/mL), and/or 0.3% Triton X-100. ***p < 0.001.
Figure 3. Exosomal miR-320b promotes lymphangiogenesis in vitro

(A) Representative images and quantification of tube formation and Transwell migration by HLECs treated with PBS, KYSE150-EXO, or EC9706-EXO. Scale bars, 100 μm. (B) Representative images and quantification of tube formation and Transwell migration by HLECs after treating with KYSE150-EXO vector or KYSE150-EXO miR-320b. Scale bars,
exosomes (EC9706-EXO kontrol) than in scramble vector-transfected KYSE150 exosome (KYSE150-EXO kontrol) and that miR-320b knockdown EC9706 released exosomes (EC9706-EXO KD; Figures 2E and 2F). To confirm that miR-320b was encapsulated within the lipid bilayer of exosomes and not directly released, we found miR-320b expression in culture medium unchanged upon RNase A treatment but significantly decreased with simultaneous treatment of RNase A and Triton X-100 together (Figure 2G).

Internalization of exosomal miR-320b by HLECs induces lymphangiogenesis

Since lymphangiogenesis is the rate-determining step for LN metastasis in ESCC,25 we investigated whether miR-320b upregulation could facilitate lymphangiogenesis in vitro. We thus analyzed the effect of ESCC cell-secreted exosomes on HLEC tube formation and migration. We found that co-incubation with ESCC-secreted exosomes dramatically increased HLEC tube formation and migration compared with PBS (Figure 3A). Moreover, the KYSE150-EXO miR-320b-derived exosome group had a higher HLEC tube formation and migration rate than the KYSE-EXO Vector group (Figure 3B). Conversely, EC9706-EXO KD co-incubation attenuated HLEC tube formation and migration rate (Figure 3C). As there is increasing evidence that suggests that AKT pathways are involved in lymphangiogenesis and lymphatic metastasis,26 we were prompted to determine whether AKT signaling pathways in HLECs could be activated by exosomal miR-320b. We found that the phosphorylation levels of AKT significantly increased in HLECs with KYSE150-EXO miR-320b compared with KYSE150-EXO Vector and PBS treatment groups (Figure 3D). These results indicate that exosomal miR-320b contributes to lymphangiogenesis in vitro.

Previous studies have demonstrated the ability of intracellular delivery of exosomal miRNAs.27 Therefore, we investigated whether communication between ESCC cells and HLECs cells was possible via miR-320b-containing exosomes. We fluorescence-labeled purified exosomes with membrane tracer PKH67 (green) and incubated them with HLECs cells. After 24 h of incubation, exosome co-cultured cells were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue) for confocal microscopy evaluation. Detection of localized green-fluorescent signal within the cytoplasm of recipient HLECs indicated exosome internalization (Figure 3E). To confirm that miR-320b is successfully transferred to HLECs via exosomes, we measured miR-320b levels in HLECs pretreated with ESCC-secreted exosomes. A significantly higher level of intracellular miR-320b was observed in recipient HLECs following treatment with KYSE150-EXO miR-320b compared with PBS and KYSE-EXO Vector treatments (Figure 3F). Moreover, prolonged incubation resulted in a corresponding increase in miR-320b levels in HLECs cells (Figure S1D). Additionally, actinomycin D (RNA polymerase II inhibitor) did not significantly alter miR-320b levels, excluding the possibility of endogenous induction of miR-320b in recipient cells (Figure S1E). Taken together, these results suggest that horizontal transfer of miR-320b from ESCC cells to HLECs can be performed intercellularly via exosomes.

ESCC-secreted exosomal miR-320b promotes LN metastasis in vivo

The effect of exosomal miR-320b on ESCC lymphangiogenesis and lymphatic metastasis was assessed in vivo using a popliteal LN metastasis model. We first randomly established footpad xenografts using luciferase-labeled KYSE150 cells, followed by intratumoral injection with PBS, KYSE150-EXO Vector, or KYSE150-EXO miR-320b, every 3 days. After eight injections, when primary tumor growth reached around 200 mm³, mice were sacrificed, and the tumors and the associated popliteal LNs were harvested for IHC analysis (Figure 4A). Interestingly, IVIS27 revealed that KYSE150-EXO Vector significantly promoted KYSE150 metastasis to the LNs compared with the PBS or KYSE150-EXO Vector-injected groups (Figure 4B). The volume of popliteal LNs in the KYSE150-EXO miR-320b-injected group was significantly larger than that in the control or KYSE150-EXO Vector groups (Figures 4C–4E). Luciferase immunostaining indicated an increased number of metastatic LNs in the KYSE150-EXO miR-320b group, which confirmed that exosomal miR-320b significantly enhanced the metastatic potential of KYSE150 cells (Figures 4F and 4G). Moreover, the KYSE150-EXO miR-320b-injected group exhibited significantly higher lymphangiogenic responses relative to the KYSE150-EXO Vector group, resulting in shorter survival times (Figures 4H and 4I). Taken together, these results revealed that exosomal miR-320b plays an integral part in LN ESCC metastasis in vivo.

ESCC-secreted exosomal miR-320b targets PDCD4 to induce lymphangiogenesis

Multiple algorithms (TargetScan and miRanda) were used to identify the candidate targets of miR-320b, from which several target genes were predicted to be regulated by miR-320b. Among these candidates, PDCD4 expression, which could suppress the AKT signaling pathway, was significantly associated with LN metastasis and was chosen for further study (Figure 5A).28–30 Dual-luciferase reporter assay in 293T cells indicated a significant and dose-dependent weakening in reporter activity for vectors containing the PDCD4 3’ UTR compared with control in the presence of miR-320b mimics (Figure 5B). When the miR-320b binding sites in the 3’ UTR were mutated, the reporter gene silencing was abrogated (Figure 5C), indicating that these are true miR-320b targeting sites. Consistent with the luciferase reporter assay results, treatment with KYSE150-EXO miR-320b but not the KYSE150-EXO Vector and PBS resulted in a significant decrease of PDCD4 expression in HLECs at both RNA
A. Insulated with K150 into footpad
Divide into groups
Footpad tumor injection
Every three days
Enucleate lymph nodes

B. PBS
KYSE150-EXO\text{vector}
KYSE150-EXO\text{msh-522b}

C. Footpad tumor
Popliteal lymph node

D. PBS
KYSE150-EXO\text{vector}
KYSE150-EXO\text{msh-522b}

E. Lymph node volume (mm$^3$)

F. HE
Anti-lucerase

G. % of specimens

H. anti-LYVE-1

I. Percent survival (%)

(legend on next page)
and protein levels (Figures 5D and 5E). Further in vitro studies confirmed that re-expression of PDCD4 rescued the downregulation of PDCD4 mediated by exosomes with high levels of miR-320b (Figure 5F). Further in vitro studies confirmed that re-expression of PDCD4 could rescue the downregulation of PDCD4 and upregulation of phosphorylated AKT level mediated by exosomes with high levels of miR-320b (Figure 5F). Most importantly, re-expression of PDCD4 abrogated KYSE150-EXOmiR-320b-mediated enhanced HLECs tube formation and migration (Figures 5G and 5H). Collectively, these results indicate that exosomal miR-320b induced lymphangiogenesis via suppression of PDCD4 expression in HLECs.

Based on these data, we further explored the pro-tumorigenic effect of miR-320b in ESCC using a subcutaneous xenograft model as previously described.36 Mice were inoculated subcutaneously with KYSE150 cells and randomly separated into three groups. Each group received intratumoral PBS, KYSE150-EXO_vector or KYSE150-EXO miR-320b every 3 days for 5 consecutive weeks (Figure 7A). KYSE150-EXO miR-320b enhanced tumor growth compared with both the KYSE150-EXO_vector and PBS group (Figure 7B). Tumors in the KYSE150-EXO miR-320b group were of greater size and weight (Figures 7C–7E) and had higher expression levels of proliferation marker Ki67 than the KYSE150-EXO_vector and PBS groups (Figure 7F). More importantly, as shown in Figure 7G, upregulated serum exosomal miR-320b levels strongly correlated with the incremental increase of Ki67-positive cells in ESCC tissues.

miR-320b overexpression is correlated with ESCC LN metastasis through promoting ESCC malignant phenotypes

Tumorigenicity is also a significant factor underlying LN metastasis and is closely associated with LN metastasis in various solid tumors, such as lung cancer,33 gastric cancer,34 and ESCC.35 To procure an overall expression profile of miR-320b in cancers, we analyzed miR-320b expression levels in several types of cancers from the Cancer Genome Atlas (TCGA) dataset (https://cancergenome.nih.gov). Almost all cancer tissues analyzed, including EC, had higher miR-320b expression levels than normal controls (Figure 6A). To verify the effect of miR-320b on the prognosis of cancer patients, we performed survival curves on Kaplan- Meier plots. As shown in Figure 6B, higher expression of miR-320b shortened the EC survival time. Collectively, these data indicated that miR-320b overexpression in EC tissues is correlated with poor outcomes in patients. Meanwhile, miR-320b was significantly upregulated in ESCC cancer cells compared with HET-1A (Figure 6C). Above all, these results indicated that miR-320b might play a crucial role in ESCC progression.

miR-320b promotes EMT progression and induces malignant phenotypes via targeting PDCD4 in ESCC cells

Functional experiments were performed to identify intracellular mediators of miR-320b-driven LN metastasis. Previous reports attribute PDCD4 as a tumor repressor gene, downregulated or lost in various cancer cells and linked with tumor progression and poor outcomes.37–41 In this study, we performed TCGA dataset analysis and reveal that PDCD4 mRNA was significantly downregulated in EC tumor tissues than adjacent normal tissues (Figure S5A). Moreover, qRT-PCR and immunoblot assay indicated that the PDCD4 mRNA and protein levels were downregulated in ESCC cells compared with HET-1A cells (Figures S3B and S3C). The above bioinformatic analysis results with TargetScan and miRanda and Dual-Luciferase reporter system have also revealed the 3’ UTR of PDCD4 contains
a binding site for miR-320b. In the present study, our data indicate PDCD4 mRNA and protein levels were lower in miR-320b overexpressing cells and higher in miR-320b knockdown cells compared to controls (Figures 8A and 8B; Figures S3D and S3E). In vivo, KYSE150-EXO-miR-320b could significantly enhance the expression level of PDCD4 protein through IHC assay (Figure S3F). Furthermore, we found an inverse correlation between miR-320b and PDCD4 mRNA levels (r = −0.412, p = 0.006) in ESCC tissues.

Figure 5. ESCC-secreted exosomal miR-320b targets PDCD4 to induce lymphangiogenesis

(A) Schematic representation of the putative predicted miR-320b targeting site in the PDCD4 mRNA 3' UTR region. (B) Relative reporter gene activity of psiCHECK2 vector bearing PDCD4 3' UTR fraction in 293T cells co-transfected with increasing amounts (1, 5, and 10 pmol) of miR-320b mimic. (C) Reporter gene activity of psiCHECK2 vector bearing PDCD4 3' UTR wild-type (WT) fraction or their mutant type (Mut) fraction in 293T cells in the presence of 10 pmol miR-320b mimics. Treatment with PBS, KYSE150-EXO(vector), or KYSE150-EXO-miR-320b on the levels of PDCD4 RNA (D) and PDCD4 protein (E) in HLECs. (F) Protein levels of PDCD4 and AKT pathway were, respectively, detected by western blot in HLECs treated with indicated exosomes in the presence of PDCD4 overexpression plasmid or vector. Representative images (G) and histogram analysis (H) of tube formation and migration by HLECs treated with KYSE150-EXO(vector) or KYSE150-EXO-miR-320b and then transfected with vector or PDCD4 plasmid. Scale bars, 100 μm. (I) ELISA assay shows the expression level of VEGF-C in the ESCC cells culture medium of different groups. **p < 0.01, ***p < 0.001.
Therefore, PDCD4 are likely functional targets of miR-320b in ESCC cells. Since PDCD4 regulates AKT signaling, we next examined whether miR-320b affects AKT signaling through PDCD4 in ESCC cells. We found that knockdown of PDCD4 expression by small interfering RNA (siRNA) substantially activated signaling as indicated by increased AKT phosphorylation (Figure S3G). The inverse effect of miR-320b has on AKT signaling through alleviating PDCD4-mediated suppression was evident in cells with miR-320b knockdown or overexpression (Figure 8B). Next, rescue assays showed that knockdown of PDCD4 partially reversed the suppression of AKT signaling due to miR-320b knockdown in malignant phenotypes of ESCC cells (Figures 8D–8J; Figures S4A–S4G). These results

(Figure 8C).

Since PDCD4 regulates AKT signaling, we next examined whether miR-320b affects AKT signaling through PDCD4 in ESCC cells. We found that knockdown of PDCD4 expression by small interfering RNA (siRNA) substantially activated signaling as indicated by increased AKT phosphorylation (Figure S3G). The inverse effect of miR-320b has on AKT signaling through alleviating PDCD4-mediated suppression was evident in cells with miR-320b knockdown or overexpression (Figure 8B). Next, rescue assays showed that knockdown of PDCD4 partially reversed the suppression of AKT signaling due to miR-320b knockdown in malignant phenotypes of ESCC cells (Figures 8D–8J; Figures S4A–S4G). These results
suggest that miR-320b acts as an upstream activator of AKT signaling and malignant phenotypes through inhibition of PDCD4 production in ESCC.

METTL3-dependent N6-methyladenosine (m6A) regulates the processing of miR-320b by DGCR8
Recently, Alarcon and colleagues demonstrated that m6A modification by METTL3 marks pri-miRNAs for recognition and processing to mature miRNA by DGCR8, which suggests that altered METTL3/m6A might contribute to the aberrant expression of miRNAs in many biological processes, including cancers. It was also previously demonstrated that METTL3 was significantly upregulated in EC tissues, compared with the adjacent tissues, which was consistent with the results from tissue samples in TCGA database (Figure 9A). We further examined METTL3 protein expression in esophageal-associated cell lines. As shown in Figure S4H, METTL3 expression was significantly upregulated in ESCC cells as compared with that in human normal esophageal epithelial cells (HET-1A), especially in EC9706 cells. To verify the role of the METTL3-m6A modification in the pri-miR-320b processing, we

Figure 7. Exosomal miR-320b promotes ESCC tumorigenesis in vivo
(A) Schematic representation of the xenograft model establishment. (B) Representative bioluminescence images of subcutaneous tumors from nude mice treated with PBS, KYSE150-EXO<sub>vector</sub>, or KYSE-EXO<sub>miR-320b</sub> (n = 5). (C) Representative images of subcutaneous tumors from nude mice treated with PBS, KYSE150-EXO<sub>vector</sub>, or KYSE-EXO<sub>miR-320b</sub> (n = 5). Tumor volume (D) was measured every 5 days and weights (E) were measured after tumor resection (n = 5). (F) Representative images of IHC staining for Ki67 expression (n = 5) in xenograft model tumor tissues. (G) Representative images of IHC staining for Ki67 expression in clinical ESCC patients’ tumor tissues. Scale bars, 50 μm. ***p < 0.001.
Molecular Therapy: Oncolytics

A. Relative expression of miR-320b in Vector and miR-320bOE.

B. Western blot analysis of PDCD4, AKT, and p-AKT in KYSE150 cells.

C. Scatter plot showing the correlation between relative expression of PDCD4 mRNA and miR-320b.

D. Table summarizing expression of miR-320b, siPDCD4, and GAPDH in KYSE150 cells.

E. Graph showing cell viability (C3455) over time in KYSE150 cells.

F. Colony formation assay in KYSE150 cells with miR-320b and shPDCD4.

G. EdU staining and EdU-positive cells in KYSE150 cells.

H. Migration and invasion assays in KYSE150 cells with miR-320b and siPDCD4.

I. Transwell cell count assay in KYSE150 cells.

J. Western blot analysis of E-cad, Vim, and GAPDH in KYSE150 cells.

(legend on next page)
used SRAMP database (http://www.cuilab.cn/sramp) to identify two putative m6A sites (RRACH sequence motifs) located in pri-miR-320b. Consistently, a positive correlation between METTL3 mRNA and miR-320b levels was observed in tumor tissues from ESCC patients (Figure 9B).

Therefore, we hypothesized that METTL3 contributes to ESCC LN metastasis by targeting miR-320b in an m6A-dependent pri-miRNA-processing manner. To elucidate the mechanism of METTL3 in the production of mature miR-320b, we compared the expression levels of pri-miR-320b, pre-miR-320b, and miR-320b in METTL3-overexpressing or knockdown cell lines (Figure 9C). Consistent with our hypothesis, overexpression of METTL3 in cells significantly decreased pri-miR-320b levels but increased both pre-miR-320b and miR-320b levels, whereas knocking down METTL3 markedly reversed this trend (Figures 9D–9F).

We further assessed whether METTL3 was required for the engagement of pri-miR-320b by the microprocessor protein DGCR8. As shown in Figure 9G, immunoprecipitation assay revealed that METTL3 co-precipitates with DGCR8 and ribonuclease treatment could weaken their interaction, suggesting that their interaction might be partly mediated by RNAs. We next observed a significant increase in m6A methylated RNA bound by DGCR8 in METTL3-overexpressing cells (Figure 9H). These findings suggest that METTL3 could manipulate pri-miR-320b processing by regulating the recognition and binding of DGCR8 to pri-miR-320b. Further, we also observed increased levels of pri-miR-320b bound to DGCR8 by qRT-PCR in METTL3-overexpressing cells compared to control when we immunoprecipitated DGCR8 (Figure 9I). Moreover, when we immunoprecipitated m6A from RNAs of control and METTL3-overexpressing cells, we found that METTL3 overexpression significantly increased the amount of pri-miR-320b modified by m6A (Figure 9J). Together, these results indicate that the METTL3 could enhance the recognition of pri-miR-320b by DGCR8, leading to processing to mature miRNA in an m6A manner.

DISCUSSION

Herein, our study demonstrated that not only was miR-320b enriched in serum exosome profiles from patients with ESCC, but serum exosomal miR-320b were positively associated with lymphatic metastasis in these patients. Moreover, we identified that tumor-secreted exosomal miR-320b could be internalized by HLECs, which enhanced AKT phosphorylation through targeting PDCD4 mRNA 3’ UTR and alleviating PDCD4-mediated suppression, resulting in the lymphangiogenesis and lymphatic metastasis of ESCC in a VEGF-C-independent manner. Additionally, intracellular expression of miR-320b in ESCC promoted its proliferation, migration, and invasion. These findings provide an in-depth mechanistic and translational insight into the pathways by which exosomal and intracellular miRNA promotes ESCC lymphatic metastasis, while supporting the emergence of miR-320b as an LN metastatic prediction marker and novel therapeutic target in ESCC (Figure 9K).

The occurrence of regional LN metastasis at an early stage is considered a crucial step in ESCC progression. Therefore, it is necessary to identify novel and effective biomarkers that discriminate between indolent and aggressive ESCC in developing personalized diagnostic and therapeutic strategies for patients with different progression risks. Our clinical data revealed that serum exosomal miR-320b was positively associated with PLVD and LN metastasis in patients with ESCC, suggesting that circulating exosomal miR-320b may serve as a potential early prediction biomarker for LN metastasis. Exosomes have been extensively studied for their function in intercellular communication between the tumor and the tumor microenvironment. Recently, cancer-secreted exosomal miRNAs have emerged as highly versatile regulators within this communication process. Zhou et al. reported that uptake of cancer-secreted miR-105 by vascular endothelial cells provoked vascular permeability and metastatic dissemination. Our results showed that ESCC-secreted miR-320b could be horizontally transferred to HLECs to promote lymphangiogenesis and facilitate lymphatic metastasis, suggesting that miR-320b may represent a potential molecular target for clinical intervention in ESCC patients with LN metastasis.

Another important finding in the present study was that cancer-secreted exosomal miR-320b downregulated PDCD4 expression in HLECs. Previous studies suggest that PDCD4 can be a critical factor for angiogenesis by regulating various signaling pathways, including VEGF-STAT3, c-jun, and AKT. Importantly, overexpression of PDCD4 in abnormal vascularization of tumors could affect Ang-2 expression and release. Hence, the induction of PDCD4 may be a new therapeutic avenue to inhibit cancer metastasis by suppressing Ang-2. Although several studies have indicated the essential role of PDCD4 in angiogenesis, cancer-induced PDCD4 transcription in HLECs remains unknown. Herein, we demonstrated that ESCC cell-secreted exosomal miR-320b downregulated PDCD4 expression in HLECs via the PDCD4 mRNA 3’ UTR binding site. PDCD4 overexpression abolished the lymphangiogenesis-stimulating effect induced by exosomal miR-320b. Therefore, our findings uncovered what we believe is a novel molecular mechanism underlying
Figure 9. METTL3-dependent m6A methylation modulates the processing of miR-320b by DGCR8

(A) TCGA database analysis of METTL3 expression in ESCA. (B) Spearman's correlation analysis between METTL3 mRNA levels and miR-320b levels in ESCC tissues (n = 43). (C) Western blot analysis shows the expression level of METTL3 mRNA and protein in METTL3 overexpress and knockdown KYSE150 cell. (D–F) METTL3

(legend continued on next page)
cancer-secreted exosomal miRNA-mediated PDCD4 downregulation in HLECs, resulting in lymphangiogenesis and LN metastasis, thus expanding the current knowledge regarding PDCD4 regulation in HLECs. It is noteworthy that exosomal miR-320b engage in the transference of genetic information, whereas lymphangiogenic growth cytokines such as VEGF-C are small proteins. These represent two different yet potentially interactive methods for signal transmission between cancer cells and HLECs. Previous studies have demonstrated that VEGF-C signaling induced lymphangiogenesis via activation of AKT pathways.49 In the present study, we found that METTL3 was upregulated in EC tissues and cells and could regulate the expression of pri-miR-320b, pre-miR-320b, and miR-320b in PDAC cells. Meanwhile, overexpression of PDCD4 in recipient ESCC cells significantly reversed the effects of miR-320b. Hence, it is possible that miR-320b activates EMT and promotes ESCC LN metastasis by directly targeting PDCD4.

As the main component in the so-called m6A “writer,” METTL3 was reported to promote bladder cancer progression by an m6A-dependent manner.48 In the present study, we found that METTL3 was upregulated in EC tissues and cells and could regulate the expression of pri-miR320b, pre-miR-320b, and miR-320b in ESCC cells. Moreover, METTL3 could interact with the microprocessor protein DGCR8 and positively modulate the pri-miR-320b process in an m6A-dependent manner. These imply that METTL3 could promote the maturation of pri-miR-320b in ESCC through m6A.

In conclusion, our data provided evidence that high levels of serum exosomal miR-320b are associated with LN metastasis and are positively correlated with PLVD in ESCC. Horizontal transfer of ESCC-secreted exosomal miR-320b into HLECs may promote lymphangiogenesis by regulating PDCD4 signaling, and intracellular miR-320b enhanced the malignant phenotypes of ESCC cells, which synergistically promotes LN metastasis. The newly identified vicious METTL3/m6A-miR-320b-PDCD4-AKT axis illustrates a critical molecular mechanism of ESCC progression and develops a potential noninvasive diagnostic approach and therapeutic strategy for ESCC patients with LN metastasis.

MATERIALS AND METHODS
Patient sample collection
A total of 366 patients underwent esophagectomy for the treatment of ESCC at the Department of General Surgery of Qilu Hospital, Cheeloo College of Medicine, Shandong University, and the Second Hospital, Cheeloo College of Medicine, Shandong University, between November 2017 and December 2020 were enrolled in this study. None of the patients had distant metastasis, underwent any prior chemo- or radiotherapy, or suffered from other co-current malignant disorders. Tumor stage was defined according to the classification guidelines of the American Joint Committee on Cancer (AJCC, 8th edition).50 All clinical patient characteristics are listed in Supplementary Table S1. This study was approved by the Clinical Research Ethics Committee of The Second Hospital, Cheeloo College of Medicine, Shandong University, and informed consent was obtained from all participants.

Cell lines and culture
Human ESCC cell lines (KYSE30, KYSE150, TE-1, EC109, and EC9706) and immortalized esophageal epithelial cell line (HET-1A) was purchased from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). KYSE30 and KYSE150 were cultured in RPMI 1640 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS). TE-1, EC109, and EC9706 cell lines were cultured in DMEM (GIBCO) supplemented with 10% FBS. HLECs were purchased from ScienCell Research Laboratories and cultured in ECM complete medium (ScienCell Research Laboratories). For exosomes co-culture, 1 μg/mL (as determined by BCA protein assay (Thermo Fisher Scientific, USA)) of exosomes were added to the culture medium of recipient cells (5 × 10⁶).

In vivo
Luciferase-labeled KYSE150 cells (5 × 10⁶) were inoculated into the footpads of BALB/c nude mice (4–5 weeks old, 18–20 g) to establish the popliteal lymphatic metastasis model. Mice were then randomly divided into three groups (n = 5 or 10 per group). PBS, KYSE150-EXO, or KYSE150-EXOEXO (5 μg/dose) was injected...
intratumorally every 3 days. LN metastasis was analyzed using an In Vivo Imaging System (Spectrum CT, PerkinElmer, USA). Footpad tumors and popliteal LNs were resected when tumor growth reached 200 mm³ (LN volume = 0.5 × width² × length). Pathological sections of primary tumors and popliteal LNs were analyzed by IHC and visualized on an inversion microscope (Zeiss, Germany). For survival analysis, mice were performed until death or 80 days after the first PBS or exosomes injection.

KYSE150 cells (5 × 10⁶ cells per mouse) were injected subcutaneously into the right back of nude mice to establish the subcutaneous tumor growth assay. 14 days later, when tumor growth reached about 200 mm³ in size, purified KYSE150-EXO_vector, or KYSE150-EXO_mir-320b (5 μg/dose) or PBS was injected intratumorally, and tumor size and body weight were measured twice weekly. Mice were sacrificed 7 weeks’ post, and tumor tissues (tumor volume = 0.5 × width² × length) were prepared for histological examination. All animal work was performed according to the Health guidelines, and protocols were approved by the Institutional Animal Care and Use Committee of Shandong University.

**Fluorescence assay**
PKH67 (Sigma-Aldrich, USA; 1 μM) was used to label exosomes according to the manufacturer’s instructions. PKH67-labeled exosomes were cocultured with HLECs for 24 h, followed by cell nuclear staining with DAPI (Invitrogen, USA). The HLECs cells were fluorescently visualized with a laser scanning microscope Axio-Imager-LSM800 (Zeiss, Germany).

**Tube formation assay**
Growth factor reduced Matrigel (BD Biosciences, CA, USA) was used to precoat 96-well plate and incubated at 37°C for 2 h, followed by tube formation of seeded 2 × 10⁴ HLECs treated with either PBS or exosomes for 6 h. The tubes were visualized with an inverted microscope, and the length of lymphatic tubes was analyzed using ImageJ software.

**RNA immunoprecipitation assay**
RNA immunoprecipitation (RIP) assays were performed using the EZ-Magna RIP kit (Millipore). Lysates of 1 × 10⁶ KYSE150 cells obtained using complete RIP lysis buffer were immunoprecipitated with RIP buffer containing anti-DGCR8 and anti-m6A antibody-conjugated dynabeads. Total RNA (input control) and isotype control (immunoglobulin G, IgG) for each antibody were assayed simultaneously. The co-precipitated pri-miR-320b were detected by qRT-PCR, which was normalized to input.

**Bioinformatics analysis**
The potential target mRNA of miR-320b was predicted using the TargetScan database and miRanda software. The m6A binding motifs of pri-miR-320b was predicted by SRAMP.

**Data availability**
The NGS data for this study are available on the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE155360. All relevant data within the scope of the paper are publicly available.

**Statistical analysis**
SPSS 17.0 for Windows (IBM, Armonk, NY) and GraphPad Prism (GraphPad Software, San Diego, CA, USA) software were used for statistical analyses. Statistical evaluations were determined using Student’s t test (two-tailed), Kruskal-Wallis test, or Spearman correlation test. Survival rates were calculated using the Kaplan-Meier method and comparisons were performed using the log-rank test. p value of 0.05 or less was considered as statistically significant.

**SUPPLEMENTAL INFORMATION**
Supplemental information can be found online at https://doi.org/10.1016/j.omto.2021.09.003.

**ACKNOWLEDGMENTS**
We thank all donors for sample donations. This work was supported by the grants from The National Natural Science Foundation of China (82002228, 81972007), Shandong Provincial Natural Science Foundation (ZR2020QH280), and The Key Research and Development Program of Shandong Province (2019GHZ003, 2020CXGC011304).

**AUTHOR CONTRIBUTIONS**
T.L. and C.W. initiated and designed the study. T.L. instructed all experiments and drafted the manuscript. P.L., J.L., Q.Q., Z.S., S.S., and T.L. conducted experiments. T.L., Y.X., Y.W., and L.D. analyzed the data. L.D. and C.W. revised the manuscript. All authors provided approval of the final manuscript.

**DECLARATION OF INTERESTS**
The authors declare no competing interests.

**REFERENCES**
1. Kayani, B., Zacharakis, E., Ahmed, K., and Hanna, G.B. (2011). Lymph node metastases and prognosis in oesophageal carcinoma—a systematic review. European journal of surgical oncology 37, 747–753.
2. Pennathur, A., Gibson, M.K., Jove, B.A., and Luketich, J.D. (2013). Oesophageal carcinoma. Lancet 381, 400–412.
3. Ohashi, S., Miyamoto, S., Kikuchi, O., Goto, T., Amanuma, Y., and Muto, M. (2015). Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology 149, 1700–1715.
4. Herrera, L.J. (2010). Extent of lymphadenectomy in esophageal cancer: how many lymph nodes is enough? Ann. Surg. Oncol. 17, 676–678.
5. Chen, C., He, W., Huang, J., Wang, B., Li, H., Cai, Q., Su, F., Bi, J., Liu, H., Zhang, B., et al. (2018). LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat. Commun. 9, 3826.
6. Wang, C., Xu, S., Tian, Y., Ju, A., Hou, Q., Liu, J., Fu, Y., and Luo, Y. (2019). Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer. Neoplasia 21, 413–427.
7. Wu, H., Song, S., Yan, A., Guo, X., Chang, L., Xu, L., Hu, L., Kuang, M., Liu, B., He, D., et al. (2020). RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. Cancer Lett. 469, 287–300.
8. Brown, M., Assen, F.P., Leithner, A., Abe, J., Schachner, H., Asfour, G., Bago-Horvath, Z., Stein, J.V., Uhрин, P., Sixt, M., and Kerjaschki, D. (2018). Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359, 1408–1411.
9. Bäng-Rudenstam, A., Cerezo-Maaga, M., and Belting, M. (2019). Pro-metastatic functions of lipoproteins and extracellular vesicles in the acidic tumor microenvironment. Cancer Metastasis Rev. 38, 79–92.
10. Krystek-Korpacz, M., Matusiewicz, M., Dąkowska, D., Grubowski, K., Blachut, K., and Banas, T. (2007). Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett. 249, 171–177.
11. Han, U., Can, O.I., Han, S., Kayhan, B., and Onal, B.U. (2007). Expressions of p53, bcl-2, and hsp-70 in squamous cell carcinoma of the upper aerodigestive tract. Anticancer Res. 27, 985–990.
12. Yang, Z., Wang, Y.G., and Su, K. (2015). VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell carcinoma. Exp. Mol. Pathol. 98, 260–266.
13. Shukla, G.C., Singh, J., and Barik, S. (2011). MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol. Cell. Pharmacol. 3, 83–92.
14. Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857–866.
15. Han, D.L., Wang, L.L., Zhang, G.Y., and Su, K. (2015). VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue. Asian Pac. J. Cancer Prev. 16, 271–274.
16. Shukla, G.C., Singh, J., and Barik, S. (2006). MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol. Cell. Pharmacol. 3, 83–92.
17. Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857–866.
18. Wang, W.W., Zhao, Z.H., Wang, L., Li, P., Chen, K.S., Zhang, J.Y., Li, W.C., Jiang, G.Z., and Li, X.N. (2019). MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. EBioMedicine 46, 66–78.
19. Lu, Y.F., Yu, J.R., Yang, Z., Zhu, G.X., Gao, P., Wang, H., Chen, S.Y., Zhang, J., Liu, M.Y., Niu, Y., et al. (2018). Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC). J. Exp. Clin. Cancer Res. 37, 301.
20. Redis, R.S., Calin, S., Yang, Y., You, M.J., and Calin, G.A. (2012). Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol. Ther. 136, 169–174.
21. Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D.W., and Simpson, R.J. (2018). Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 15, 617–638.
22. Zhang, Z.G., Buller, B., and Chopp, M. (2019). Exosomes - beyond stem cells for restorative therapy in stroke and neurological injury. Nat. Rev. Neurol. 15, 193–203.
23. Fang, J.H., Zhang, Z.I., Shang, L.R., Luo, Y.W., Lin, Y.F., Yuan, Y., and Zhaung, S.M. (2018). Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology 68, 1459–1475.
24. Cheng, M., Yang, J., Zhao, X., Zhang, E., Zeng, Q., Yu, Y., Yang, L., Wu, B., Yi, G., Mao, X., et al. (2019). Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. Nat. Commun. 10, 959.
25. Xu, G., Zhang, B., Ye, J., Cao, S., Shi, J., Zhao, Y., Wang, Y., Sang, J., Yao, Y., Guan, W., et al. (2019). Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression. Int. J. Biol. Sci. 15, 2320–2329.
26. Mathieu, M., Martin-Jaular, J., Lavieu, G., and Thrë, C. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17.
27. Ji, H., Cao, R., Yang, Y., Zhang, Y., Iwamoto, H., Lim, S., Nakamura, M., Andersson, P., Wang, J., Sun, Y., et al. (2014). TNFR1 mediates TNF-α-induced tumor lymphangiogenesis and metastasis by modulating VEGF-C/VEGFR3 signalling. Nat. Commun. 5, 4944.
45. Fan, B., Jin, Y., Zhang, H., Zhao, R., Sun, M., Sun, M., Yuan, X., Wang, W., Wang, X., Chen, Z., et al. (2020). MicroRNA-21 contributes to renal cell carcinoma cell invasiveness and angiogenesis via the PDCD4/c-Jun (AP-1) signalling pathway. Int. J. Oncol. 56, 178–192.

46. Pin, G., Huanting, L., Chengzhan, Z., Xinjuan, K., Yugong, F., Wei, L., Shifang, L., Zhaojian, L., Kun, H., Weicheng, Y., et al. (2020). Down-Regulation of PDCD4 Promotes Proliferation, Angiogenesis and Tumorigenesis in Glioma Cells. Front. Cell Dev. Biol. 8, 593685.

47. Song, S., and Qiu, X. (2021). LncRNA miR503HG inhibits epithelial-mesenchymal transition and angiogenesis in hepatocellular carcinoma by enhancing PDCD4 via regulation of miR-15b. Digestive and liver disease 53, 107–116.

48. Krug, S., Huth, J., Göke, F., Buchholz, M., Gress, T.M., Göke, R., and Lankat-Buttgereit, B. (2012). Knock-down of Pdcd4 stimulates angiogenesis via up-regulation of angiopoietin-2. Biochim. Biophys. Acta 1823, 789–799.

49. Cheng, M., Sheng, L., Gao, Q., Xiong, Q., Zhang, H., Wu, M., Liang, Y., Zhu, F., Zhang, Y., Zhang, X., et al. (2019). The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene 38, 3667–3680.

50. Rice, T.W., Ishwaran, H., Hofstetter, W.L., Kelsen, D.P., Apperson-Hansen, C., and Blackstone, E.H.; Worldwide Esophageal Cancer Collaboration I (2016). Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. In Diseases of the esophagus, 29, pp. 897–905.